Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 8/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 7/20 | 0.38 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32687983 | 0.92 | CXCR2 (0.41) | RAPGEF4CXCR2ACMSDKDM4ERECQL | |
| SCHEMBL32688486 | 0.82 | RAPGEF4 (0.44) | RAPGEF4JAK2JAK1TYK2JAK3 | |
| SCHEMBL15188821 | 0.79 | RAPGEF4 (0.53) | RAPGEF4JAK2JAK1TYK2JAK3 | |
| SCHEMBL15188812 | 0.77 | RAPGEF4 (0.51) | RAPGEF4JAK2JAK1TYK2JAK3 | |
| SCHEMBL32688159 | 0.73 | CXCR2 (0.41) | RAPGEF4CXCR2ACMSDKDM4EPKM | |
| SCHEMBL19501267 | 0.73 | RAPGEF4 (0.42) | RAPGEF4JAK2JAK1TYK2JAK3 | |
| SCHEMBL15188837 | 0.70 | CXCR2 (0.50) | RAPGEF4JAK2JAK1TYK2JAK3 | |
| SCHEMBL20339831 | 0.70 | KDM4E (0.51) | RAPGEF4JAK2JAK1TYK2JAK3 | |
| SCHEMBL32688202 | 0.69 | RAPGEF4 (0.44) | RAPGEF4JAK2JAK1TYK2JAK3 | |
| SCHEMBL19499969 | 0.66 | RAPGEF4 (0.67) | RAPGEF4JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | ORSOBIO INC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | CPT1B, CBR1, MUSK | RAPGEF4 4386/4885JAK2 4593/4885JAK1 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.